Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
CJC-1295 + Ipamorelin is a USA-manufactured dual-peptide GH axis research blend combining CJC-1295 No DAC (ModGRF 1-29) a synthetic GHRH analogue that activates the GHRH receptor on anterior pituitary somatotrophs via Gs-cAMP signaling and Ipamorelin, a selective GH secretagogue that activates the ghrelin receptor (GHS-R1a) via the distinct Gq/11 intracellular pathway, providing simultaneous dual-receptor GH axis stimulation in a single research preparation
Additional semaglutide risks include pancreatitis, gallbladder disease, acute kidney injury, and diabetic retinopathy complications in patients with diabetes
Persistent side effects beyond 2 weeks after a dose increase Transient nausea, mild constipation, and decreased appetite are expected and normal during the 1 to 2 weeks after each dose increase
The Journal of Physiology, 589(Pt 4), 963973
